CareDx, Inc. (CDNA) News

CareDx, Inc. (CDNA): $22.51

-1.77 (-7.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CDNA News Items

CDNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CDNA News Highlights

  • For CDNA, its 30 day story count is now at 17.
  • Over the past 23 days, the trend for CDNA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about CDNA are MIRO, PEAK and REG.

Latest CDNA News From Around the Web

Below are the latest news stories about CareDx Inc that investors may wish to consider to help them evaluate CDNA as an investment opportunity.

CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript

CareDx, Inc (CDNA) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Ian Cooney - Vice President of Investor Relations Reg Seeto - President & Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Dipesh Patel -...

SA Transcripts on Seeking Alpha | February 25, 2022

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

CareDx Reports Fourth Quarter and Full Year 2021 Results

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights: Achieved total revenue of $79.2 million for the three months ended December 31, 2021, increasing 35% ove

Yahoo | February 24, 2022

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World''s First Successful Living Xenotransplantation

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world''s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022. Surgeons from the University of Maryland School of Medicine (UMSOM) are using adapted versions of two complementary, non-invasive CareDx surveillance solutions, experimentally, t...

Benzinga | February 22, 2022

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring Worlds First Successful Living Xenotransplantation

CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health

GlobeNewswire | February 22, 2022

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation

CareDx’s Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ HealthSOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor pos

Yahoo | February 22, 2022

CareDx to Report Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewswire | February 17, 2022

On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately NeedSOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that in commemoration of National Donor Day, held o

Yahoo | February 14, 2022

Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA)

CareDx Inc (NASDAQ:CDNA)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.67. At the close of trading, the stocks price was $43.20, to imply a decrease of -2.33% or -$1.03 in intraday trading. The CDNA shares 52-week high remains $96.88, putting it -124.26% down since that peak Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA) Read More »

Marketing Sentinel | February 12, 2022

Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022

EDEN PRAIRIE, Minn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will ring the closing bell at Nasdaq on Monday, February 14, 2022, at 4:00 p.m. ET to celebrate National Donor Day and the Company’s public listing last year on Nasdaq under the trading symbol MIRO. Miromatrix CEO, Jeff Ross, Ph.D., wi

Yahoo | February 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5598 seconds.